An Oncofetal Glycosaminoglycan Modification Provides Therapeutic Access to Cisplatin-resistant Bladder Cancer.

Seiler, Roland; Oo, Htoo Zarni; Tortora, Davide; Clausen, Thomas M; Wang, Chris K; Kumar, Gunjan; Pereira, Marina Ayres; Ørum-Madsen, Maj S; Agerbæk, Mette Ø; Gustavsson, Tobias; Nordmaj, Mie A; Rich, Jamie R; Lallous, Nada; Fazli, Ladan; Lee, Sherry S; Douglas, James; Todenhöfer, Tilman; Esfandnia, Shaghayegh; Battsogt, Dulguun; Babcook, John S; ... (2017). An Oncofetal Glycosaminoglycan Modification Provides Therapeutic Access to Cisplatin-resistant Bladder Cancer. European urology, 72(1), pp. 142-150. Elsevier 10.1016/j.eururo.2017.03.021

Text Seiler_EurUrol_An oncofetal glycosaminoglycan.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (4MB) | Request a copy

BACKGROUND

Although cisplatin-based neoadjuvant chemotherapy (NAC) improves survival of unselected patients with muscle-invasive bladder cancer (MIBC), only a minority responds to therapy and chemoresistance remains a major challenge in this disease setting.

OBJECTIVE

To investigate the clinical significance of oncofetal chondroitin sulfate (ofCS) glycosaminoglycan chains in cisplatin-resistant MIBC and to evaluate these as targets for second-line therapy.

DESIGN, SETTING, AND PARTICIPANTS

An ofCS-binding recombinant VAR2CSA protein derived from the malaria parasite Plasmodium falciparum (rVAR2) was used as an in situ, in vitro, and in vivo ofCS-targeting reagent in cisplatin-resistant MIBC. The ofCS expression landscape was analyzed in two independent cohorts of matched pre- and post-NAC-treated MIBC patients.

INTERVENTION

An rVAR2 protein armed with cytotoxic hemiasterlin compounds (rVAR2 drug conjugate [VDC] 886) was evaluated as a novel therapeutic strategy in a xenograft model of cisplatin-resistant MIBC.

OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS

Antineoplastic effects of targeting ofCS.

RESULTS AND LIMITATIONS

In situ, ofCS was significantly overexpressed in residual tumors after NAC in two independent patient cohorts (p<0.02). Global gene-expression profiling and biochemical analysis of primary tumors and cell lines revealed syndican-1 and chondroitin sulfate proteoglycan 4 as ofCS-modified proteoglycans in MIBC. In vitro, ofCS was expressed on all MIBC cell lines tested, and VDC886 eliminated these cells in the low-nanomolar IC50 concentration range. In vivo, VDC886 effectively retarded growth of chemoresistant orthotopic bladder cancer xenografts and prolonged survival (p=0.005). The use of cisplatin only for the generation of chemoresistant xenografts are limitations of our animal model design.

CONCLUSIONS

Targeting ofCS provides a promising second-line treatment strategy in cisplatin-resistant MIBC.

PATIENT SUMMARY

Cisplatin-resistant bladder cancer overexpresses particular sugar chains compared with chemotherapy-naïve bladder cancer. Using a recombinant protein from the malaria parasite Plasmodium falciparum, we can target these sugar chains, and our results showed a significant antitumor effect in cisplatin-resistant bladder cancer. This novel treatment paradigm provides therapeutic access to bladder cancers not responding to cisplatin.

Interest & Impact

Downloads

2 since deposited on 22 Feb 2018
0 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item